AWM Investment Company Inc. Makes New $996,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)

AWM Investment Company Inc. purchased a new stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 400,000 shares of the company's stock, valued at approximately $996,000. AWM Investment Company Inc. owned about 0.57% of Nkarta at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NKTX. Invesco Ltd. purchased a new stake in Nkarta in the 4th quarter valued at approximately $30,000. Sequoia Financial Advisors LLC acquired a new position in shares of Nkarta in the fourth quarter worth $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta in the fourth quarter valued at $37,000. ProShare Advisors LLC purchased a new stake in shares of Nkarta in the fourth quarter valued at $45,000. Finally, Catalina Capital Group LLC boosted its stake in shares of Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock valued at $47,000 after acquiring an additional 6,867 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Trading Up 5.9%

NASDAQ:NKTX opened at $1.80 on Wednesday. The firm's fifty day simple moving average is $1.79 and its 200 day simple moving average is $2.18. The firm has a market capitalization of $127.72 million, a price-to-earnings ratio of -0.96 and a beta of 0.81. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $8.23.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. On average, analysts predict that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on NKTX shares. HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. William Blair reissued a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. Needham & Company LLC decreased their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, Stifel Nicolaus dropped their price objective on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Nkarta has a consensus rating of "Buy" and a consensus target price of $14.67.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.